Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015–16 | Zendy

David M. Livermore | Zendy; Danièle Meunier | Zendy; Katie L. Hopkins | Zendy; Michel Doumith | Zendy; Robert L. Hill | Zendy; Rachel Pike | Zendy; Peter Staves | Zendy; Neil Woodford | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015–16

Author(s) -

David M. Livermore,

Danièle Meunier,

Katie L. Hopkins,

Michel Doumith,

Robert L. Hill,

Rachel Pike,

Peter Staves,

Neil Woodford

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx438

Subject(s) - ceftazidime , ceftazidime/avibactam , avibactam , cephalosporin , microbiology and biotechnology , klebsiella pneumoniae , pseudomonas aeruginosa , enterobacteriaceae , biology , ertapenem , acinetobacter baumannii , agar dilution , efflux , antibiotic resistance , antibiotics , meropenem , minimum inhibitory concentration , escherichia coli , bacteria , gene , genetics

Ceftazidime/avibactam combines an established oxyimino-cephalosporin with the first diazabicyclooctane β-lactamase inhibitor to enter clinical use. We reviewed its activity against Gram-negative isolates, predominantly from the UK, referred for resistance investigation in the first year of routine testing, beginning in July 2015.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research